As a new year beckons, there is considerable anticipation that many drug makers will vigorously lift a self-imposed moratorium on price hikes that began last summer in response to political pressure from President Trump. After all, the pharmaceutical industry traditionally boosts prices in January in order to meet financial goals. Moreover, White House efforts to staunch rising drug costs have yielded few gains.

Already, a few companies have signaled higher prices are coming, but what might these look like?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • It seems like the drug manufacturers are almost begging for some kind of government intervention … a bizarre maneuver for short-term shareholder gain.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy